Rating Change
UBS analysts reiterated a Buy rating on Tenet Healthcare Corporation (NYSE:THC) on July 27, 2026.
reiterateNYSE:THC
UBS Reiterates Buy Rating on Tenet Healthcare Corporation (THC)
Rating Change UBS analysts reiterated a Buy rating on Tenet Healthcare Corporation (NYSE:THC) on July 27, 2026. Market Context Tenet Healthcare Corporation operates in the…
Market Context
Tenet Healthcare Corporation operates in the Healthcare sector. The stock currently trades at $243.36 with a market capitalization of $17.4B. The stock has gained 52.4% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tenet Healthcare Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Tenet Healthcare Corporation
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 27, 2026 | Morgan Stanley | Overweight | N/A |
| Jul 27, 2026 | TD Cowen | Buy | N/A |
| Jul 27, 2026 | UBS | Buy | N/A |
| Jul 27, 2026 | RBC Capital | Outperform | N/A |
| Jul 24, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View THC Stock Page
Frequently Asked Questions
What does a Buy rating mean for THC?
A Buy rating from UBS reflects the analyst's outlook on Tenet Healthcare Corporation (NYSE:THC). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the THC forecast page.